Loading company…
Basel company founded in 2017 developing non-opioid therapies for painful diabetic and chemotherapy-induced neuropathy.
Novaremed AG, founded in 2017 and headquartered in Basel, Switzerland, develops non-opioid therapies for chronic pain, focusing on painful diabetic peripheral neuropathy and chemotherapy-induced peripheral neuropathy. Its lead product NRD.E1 is an orally active small molecule in a Phase 2b trial sponsored by the NIH, and MP-101 is a Phase 2 candidate to prevent CIPN. The company has raised USD 50.00 mn in total, most recently in January 2021 led by Global Emerging Markets, and has completed 5 deals. It is at the Series B stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in